Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3929
Source ID: NCT01196546
Associated Drug: Vildagliptin/Metformin
Title: Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: vildagliptin/metformin
Outcome Measures: Primary: HbA1c reduction, 24 weeks after treatment | Secondary: Proportion of patients who achieve target of HbA1c<6.5% at the end of study, 24 weeks after treatment|To evaluate the effect of combination therapy of vildagliptin (50 mg) plus metformin (500 or 1000 mg) twice daily on FPG and BMI, safety and tolerability profiles, 24 weeks after treatment
Sponsor/Collaborators: Sponsor: Novartis
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 161
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2010-03
Completion Date: 2011-10
Results First Posted:
Last Update Posted: 2017-08-01
Locations: BMA Medical College and Vajira Hospital, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Phamongkutklao Hospital, Bangkok, Thailand|Police General Hospital, Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Khon Kaen Hospital, Khon Kaen, Thailand|Fort Suranaree Hospital, Nakhon Ratchasima, Thailand|Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand
URL: https://clinicaltrials.gov/show/NCT01196546